|
?:authorAffiliation
|
-
[\'Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.\', \'Harvard University School of Engineering and Applied Sciences, Cambridge, MA, USA.\', \'National Center of Biotechnology Information, National Institutes of Health, Bethesda, MD, USA.\', \'Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.\', \'Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH, USA.\', \'Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Aikaterini.alexaki@fda.hhs.gov.\', \'Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. Chava.kimchi-sarfaty@fda.hhs.gov.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}